Molnupiravir or Placebo in Patients with Covid-19 Molnupiravir is an oral agent, a metabolite of which has activity against SARS-CoV-2. In a controlled phase 2 trial in adults hospitalized for Covid-19 who had symptoms for 10 days or less prior to randomization, patients received placebo (n=75) or varying doses of molnupiravir (n=218) administered twice daily for 5 days. There was no impact of treatment on death. Median time to sustained recovery was 9 days in all groups, with day 29 recovery rates ranging from 81.5 to 85.2%. There were no dose-limiting side effects or adverse events.